Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGA039 in Adolescent and Adult Patients With Von Willebrand Disease
NCT07115004Phase 3Recruiting
- Sponsor
- Vega Therapeutics
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of vga039 in von Willebrand disease (VWD), sponsored by Vega Therapeutics. Primary endpoint: Incidence of bleeding events at 49 weeks. Started Oct 2025; status: recruiting.
02
Drugs
vga039
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT07115004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115004.